Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc..
OBJECTIVES: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T-cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers multiple cytokines primarily involving the Th1/Th17 pathway. The primary objective of this study was to assess the impact of itolizumab in arresting the lung function deterioration of COVID-19 patients. Secondary objectives included safety, duration of ventilation, 14-day mortality and evaluation of interleukin 6 concentration.
METHODS: Patients with confirmed SARS-CoV-2 received itolizumab in combination with other therapies included in the national protocol for COVID-19.
RESULTS: Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2/FiO2 ratio and reduced FiO2 requirements. Ventilation time was 8 days for critical and 1 day for severe cases. Ten patients had related adverse events while 3 subjects developed related serious events. In 30 patients, interleukin 6 decreased in individuals with high level and did not change in those with lower concentration. Fourteen-day lethality rate was 4% and 18% for moderate and severe patients, respectively. The proportion of moderate or severe patients with ventilation or death at day 14 was 9.8%. Time to treatment, neurological manifestations and biomarkers such as NLR were significantly associated with higher lethality.
CONCLUSIONS: The opportune administration of itolizumab might interrupt the hyperinflammatory cascade and prevent COVID-19 morbidity and mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Clinical & translational immunology - 9(2020), 11 vom: 27., Seite e1218 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Caballero, Armando [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD6 |
|---|
| Anmerkungen: |
Date Revised 18.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/cti2.1218 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318699311 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318699311 | ||
| 003 | DE-627 | ||
| 005 | 20231225165910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cti2.1218 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318699311 | ||
| 035 | |a (NLM)33304584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caballero, Armando |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. | ||
| 520 | |a OBJECTIVES: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T-cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers multiple cytokines primarily involving the Th1/Th17 pathway. The primary objective of this study was to assess the impact of itolizumab in arresting the lung function deterioration of COVID-19 patients. Secondary objectives included safety, duration of ventilation, 14-day mortality and evaluation of interleukin 6 concentration | ||
| 520 | |a METHODS: Patients with confirmed SARS-CoV-2 received itolizumab in combination with other therapies included in the national protocol for COVID-19 | ||
| 520 | |a RESULTS: Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2/FiO2 ratio and reduced FiO2 requirements. Ventilation time was 8 days for critical and 1 day for severe cases. Ten patients had related adverse events while 3 subjects developed related serious events. In 30 patients, interleukin 6 decreased in individuals with high level and did not change in those with lower concentration. Fourteen-day lethality rate was 4% and 18% for moderate and severe patients, respectively. The proportion of moderate or severe patients with ventilation or death at day 14 was 9.8%. Time to treatment, neurological manifestations and biomarkers such as NLR were significantly associated with higher lethality | ||
| 520 | |a CONCLUSIONS: The opportune administration of itolizumab might interrupt the hyperinflammatory cascade and prevent COVID-19 morbidity and mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD6 | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a SARS‐CoV2 | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a itolizumab | |
| 650 | 4 | |a monoclonal antibody | |
| 700 | 1 | |a Filgueira, Lázaro M |e verfasserin |4 aut | |
| 700 | 1 | |a Betancourt, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Naivy |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Despaigne, Rolando E |e verfasserin |4 aut | |
| 700 | 1 | |a Escalona, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz, Henrry |e verfasserin |4 aut | |
| 700 | 1 | |a Meriño, Elio |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Lilia M |e verfasserin |4 aut | |
| 700 | 1 | |a Castillo, Ulises |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Mayra |e verfasserin |4 aut | |
| 700 | 1 | |a Saavedra, Danay |e verfasserin |4 aut | |
| 700 | 1 | |a García, Yanelda |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Geydi |e verfasserin |4 aut | |
| 700 | 1 | |a Cepeda, Meylán |e verfasserin |4 aut | |
| 700 | 1 | |a Arencibia, Maylén |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrera, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Domecq, Milagros |e verfasserin |4 aut | |
| 700 | 1 | |a Estévez, Daymys |e verfasserin |4 aut | |
| 700 | 1 | |a Valenzuela, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Lizet |e verfasserin |4 aut | |
| 700 | 1 | |a Mazorra, Zaima |e verfasserin |4 aut | |
| 700 | 1 | |a León, Kalet |e verfasserin |4 aut | |
| 700 | 1 | |a Crombet, Tania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational immunology |d 2012 |g 9(2020), 11 vom: 27., Seite e1218 |w (DE-627)NLM244580189 |x 2050-0068 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:11 |g day:27 |g pages:e1218 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cti2.1218 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 11 |b 27 |h e1218 | ||